243 related articles for article (PubMed ID: 29558031)
1. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases.
Krela-Kaźmierczak I; Szymczak-Tomczak A; Łykowska-Szuber L; Wysocka E; Michalak M; Stawczyk-Eder K; Waszak K; Linke K; Eder P
Adv Clin Exp Med; 2018 Apr; 27(4):449-453. PubMed ID: 29558031
[TBL] [Abstract][Full Text] [Related]
2. Bone density and bone metabolism in patients with inflammatory bowel disease.
Shirazi KM; Somi MH; Rezaeifar P; Fattahi I; Khoshbaten M; Ahmadzadeh M
Saudi J Gastroenterol; 2012; 18(4):241-7. PubMed ID: 22824766
[TBL] [Abstract][Full Text] [Related]
3. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
5. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis.
Stanisławowski M; Wiśniewski P; Guzek M; Wierzbicki PM; Adrych K; Smoczyński M; Sworczak K; Celiński K; Kmieć Z
J Crohns Colitis; 2014 Aug; 8(8):802-10. PubMed ID: 24439762
[TBL] [Abstract][Full Text] [Related]
6. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region.
Krela-Kaźmierczak I; Michalak M; Szymczak-Tomczak A; Łykowska-Szuber L; Stawczyk-Eder K; Waszak K; Kucharski MA; Dobrowolska A; Eder P
Pol Arch Intern Med; 2018 Aug; 128(7-8):447-454. PubMed ID: 30057387
[TBL] [Abstract][Full Text] [Related]
9. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
10. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor (VDR) TaqI polymorphism, vitamin D and bone mineral density in patients with inflammatory bowel diseases.
Szymczak-Tomczak A; Krela-Kaźmierczak I; Kaczmarek-Ryś M; Hryhorowicz S; Stawczyk-Eder K; Szalata M; Skrzypczak-Zielińska M; Łykowska-Szuber L; Eder P; Michalak M; Dobrowolska A; Słomski R
Adv Clin Exp Med; 2019 Jul; 28(7):955-960. PubMed ID: 30929318
[TBL] [Abstract][Full Text] [Related]
12. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
Moschen AR; Kaser A; Enrich B; Ludwiczek O; Gabriel M; Obrist P; Wolf AM; Tilg H
Gut; 2005 Apr; 54(4):479-87. PubMed ID: 15753532
[TBL] [Abstract][Full Text] [Related]
13. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease.
Tan B; Li P; Lv H; Li Y; Wang O; Xing XP; Qian JM
J Dig Dis; 2014 Mar; 15(3):116-23. PubMed ID: 24354597
[TBL] [Abstract][Full Text] [Related]
16. Updated bone mineral density status in Saudi patients with inflammatory bowel disease.
Ewid M; Al Mutiri N; Al Omar K; Shamsan AN; Rathore AA; Saquib N; Salaas A; Al Sarraj O; Nasri Y; Attal A; Tawfiq A; Sherif H
World J Gastroenterol; 2020 Sep; 26(35):5343-5353. PubMed ID: 32994692
[TBL] [Abstract][Full Text] [Related]
17. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
18. Femoral neck osteopenia in patients with inflammatory bowel disease.
Pollak RD; Karmeli F; Eliakim R; Ackerman Z; Tabb K; Rachmilewitz D
Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
Jahnsen J; Falch JA; Mowinckel P; Aadland E
Scand J Gastroenterol; 2004 Feb; 39(2):145-53. PubMed ID: 15000276
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density in Iranian patients with inflammatory bowel disease.
Zali M; Bahari A; Firouzi F; Daryani NE; Aghazadeh R; Emam MM; Rezaie A; Shalmani HM; Naderi N; Maleki B; Sayyah A; Bashashati M; Jazayeri H; Zand S
Int J Colorectal Dis; 2006 Dec; 21(8):758-66. PubMed ID: 16463035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
